Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
77 hedge funds and large institutions have $123M invested in Kezar Life Sciences in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 10 closing their positions.
13% more capital invested
Capital invested by funds: $109M → $123M (+$13.7M)
12% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 26
0.08% more ownership
Funds ownership: 5.01% → 5.09% (+0.08%)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
1% less funds holding
Funds holding: 78 → 77 (-1)
93% less call options, than puts
Call options by funds: $5K | Put options by funds: $70K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$4.75M |
| 2 |
BlackRock
New York
|
+$2.92M |
| 3 |
Millennium Management
New York
|
+$1.53M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.35M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$477K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.51M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$2.42M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$1.77M |
| 4 |
CA
CHI Advisors
New York
|
-$621K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$474K |
KZR Hedge Fund Activity: Q4 2020 in Review
77 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q4 2020, worth a combined $123M — up 13% from $109M a quarter earlier.
Fund positioning in KZR was balanced in Q4 2020: 10 funds opened new positions, 10 closed out, 29 added to existing stakes and 26 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $4.75M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $4.51M sold.
- 77 institutional investors held Kezar Life Sciences (KZR) as of Q4 2020, down from 78 in Q3 2020.
- Funds reported $123M of Kezar Life Sciences stock for Q4 2020, up 13% quarter-over-quarter.
- 10 funds opened new Kezar Life Sciences positions in Q4 2020 and 10 closed out, a net change of 0 holders.
- The largest Kezar Life Sciences buyer in Q4 2020 was Suvretta Capital Management, an estimated $4.75M added.
- The largest Kezar Life Sciences seller in Q4 2020 was Cormorant Asset Management, an estimated $4.51M sold.
Based on aggregated 13F filings for Q4 2020.